Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Phase 3
Terminated
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02183246
Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02183662
Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: GINSANA
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02182882
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis
Phase 2
Completed
- Conditions
- Pharyngitis
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 390
- Registration Number
- NCT02183038
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Hypertension
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 166
- Registration Number
- NCT02182830
- Locations
- 🇺🇸
Atlanta Clinical Research Centers, Atlanta, Georgia, United States
🇺🇸Albert F. Johary MD, PC, Dunwoody, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: BIBF 1120 low doseDrug: BIBF 1120 high dose
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT02182063
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 82
- Registration Number
- NCT02183155
Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Meloxicam, low doseDrug: Meloxicam, medium doseDrug: Meloxicam, high dose
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02181309
Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 684
- Registration Number
- NCT02181335
Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02181322
© Copyright 2025. All Rights Reserved by MedPath